Literature DB >> 18452128

Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.

A Lopez-Beltran1, J Alvarez-Kindelan, R J Luque, A Blanca, A Quintero, R Montironi, L Cheng, R Gonzalez-Campora, M J Requena.   

Abstract

Tumour recurrence has a major impact on patients with non-invasive papillary urothelial tumours of the bladder. To explore the role of DBC1 (deleted in bladder cancer 1 locus), a candidate tumour suppressor gene located at 9q32-33, as prognostic marker we have performed loss of heterozygosity (LOH) testing in 49 patients with primary papillary urothelial tumours and associated normal urothelium. Data from the 38 tumours and 11 specimens of normal urothelium that were informative in the LOH study (D9S195 marker) showed that LOH in urothelium (45.4%) but not in non-invasive tumours (60.5%) was associated with tumour recurrence (p = 0.026) but not to grade or progression. Also, tumours whose normal urothelium had LOH were larger (p = 0.020) and showed cyclin D1 over-expression (p = 0.032). Non-significant increased expression of p53, p21Waf1, apoptotic index and tumour proliferation, and decreased expression of p27Kip1 or cyclin D3 also characterized tumours whose normal urothelium had LOH. The expression of these G1-S modulators, apoptotic index and tumour proliferation was more heterogeneous in papillary urothelial tumours, irrespective of having retained heterozygosity or LOH. Also, Bax expression decreased in papillary urothelial tumours having LOH (p = 0.0473), but Bcl-2 was unrelated to LOH status. In addition, FGFR3 protein expression decreased in LOH tumours (p = 0.036) and in those having LOH in their normal urothelium (p = 0.022). FGFR3 immunohistochemical expression was validated by western blot in selected cases. The survival analysis selected LOH in normal urothelium as a marker of disease-free survival (log-rank 5.32, p = 0.021), progression-free survival (log-rank 3.97, p = 0.046) and overall survival (log-rank 4.26, p = 0.038); LOH in tumours was significant in progression-free survival (log-rank 3.83, p = 0.042). It is concluded that LOH at the DBC1 locus in normal urothelium seems to be relevant in the prognosis of non-invasive papillary tumours of the bladder via selecting cases with increased proliferation, frequent alterations of the G1-S phase modulators, and decreased FGFR3 protein expression. Copyright (c) 2008 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452128     DOI: 10.1002/path.2353

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  5 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

2.  Bladder cancer: Normal cystoscopy, malignant cytology in NMIBC: why biopsy?

Authors:  Antonio Lopez-Beltran
Journal:  Nat Rev Urol       Date:  2014-08-26       Impact factor: 14.432

Review 3.  [Tumorigenesis from a pathological perspective : Tumor spread and epigenetically regulated genes in bladder cancer].

Authors:  N T Gaisa
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

4.  Description of longitudinal tumor evolution in a case of multiply relapsed clear cell sarcoma of the kidney.

Authors:  Tomoki Yaguchi; Shunsuke Kimura; Masahiro Sekiguchi; Yasuo Kubota; Masafumi Seki; Kenichi Yoshida; Yuichi Shiraishi; Keisuke Kataoka; Yoichi Fujii; Kentaro Watanabe; Mitsuteru Hiwatari; Satoru Miyano; Seishi Ogawa; Junko Takita
Journal:  Cancer Rep (Hoboken)       Date:  2021-12-29

5.  Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer.

Authors:  Ui Jae Shim; Il-Seok Lee; Ho Won Kang; Jayoung Kim; Won Tae Kim; Isaac Yi Kim; Keun Ho Ryu; Yung Hyun Choi; Sung-Kwon Moon; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Wun-Jae Kim
Journal:  Korean J Urol       Date:  2013-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.